Not available
Quote | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Last: | $8 |
---|---|
Change Percent: | 0.0% |
Open: | $8 |
Close: | $8 |
High: | $8 |
Low: | $8 |
Volume: | 625 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
News | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to ...
2024-03-13 10:01:09 ET Silence Therapeutics plc (SLN) Q4 2023 Earnings Conference March 13, 2024 08:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations & Corporate Communications Craig Tooman - President & Chief Executive Officer Rhonda...
Message Board Posts | Silence Therapeutics Ord (OTCMKTS:SLNCF)
Subject | By | Source | When |
---|---|---|---|
Emylers: SLNCF Financials 07/16/2014 14:39:30 Silence Therapeutics, Plc. Period Ending Total Revenue | Emylers | investorshangout | 07/16/2014 7:39:26 PM |
Silence Therapeutics plc Rating Reiterated by Canaccord Genuity (SLN) | Wildbilly | investorshub | 03/12/2014 5:26:04 PM |
Silence Therapeutics A Quieter Name In RNAi | Wildbilly | investorshub | 03/12/2014 5:18:37 PM |
Stock_Tracker: Latest Silence Therapeutics (SLNCF) Headlines Global RNAi Drug Delivery Market 2014-2 | Stock_Tracker | investorshangout | 03/11/2014 1:26:09 PM |
chartguy89: SLNCF 6.30 Stock Charts $SLNCF 1 Month Chart | chartguy89 | investorshangout | 03/10/2014 1:16:26 AM |
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Ord Company Name:
SLNCF Stock Symbol:
OTCMKTS Market:
Published findings demonstrate zerlasiran was well-tolerated and significantly reduced Lp(a) after single and multiple dosing Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to ...
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company to host conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN (“Silence” or ...
Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase 1 results Topline 48-week data expected in 2Q 2024 Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the ...